scholarly journals Failure of Posaconazole Therapy in a Renal Transplant Patient with Invasive Aspergillosis Due to Aspergillus fumigatus with Attenuated Susceptibility to Posaconazole

2011 ◽  
Vol 55 (7) ◽  
pp. 3564-3566 ◽  
Author(s):  
Saskia Kuipers ◽  
Roger J. M. Brüggemann ◽  
Ruud G. L. de Sévaux ◽  
John P. F. A. Heesakkers ◽  
Willem J. G. Melchers ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Invasive Aspergillosis ◽  
Aspergillus Fumigatus ◽  
Drug Exposure ◽  
Renal Transplant Patient ◽  
Transplant Patient ◽  
Kidney Transplant Recipient ◽  
Time Curve ◽  
Content Type ◽  
Concentration Time

ABSTRACTWe report the case of a kidney transplant recipient with invasive aspergillosis due toAspergillus fumigatusresistant to voriconazole and intermediately susceptible to posaconazole who failed posaconazole therapy. Plasma posaconazole concentrations indicated an unfavorable ratio of the area under the concentration-time curve over the MIC. Posaconazole should be used with caution for invasive aspergillosis caused by strains with attenuated posaconazole susceptibility, as drug exposure may be inadequate, resulting in therapeutic failure.

scholarly journals First Case of Disseminated Infection with Nocardia cerradoensis in a Human

2015 ◽  
Vol 53 (3) ◽  
pp. 1034-1037 ◽  
Author(s):  
Caroline Piau ◽  
Mallorie Kerjouan ◽  
Marc Le Mouel ◽  
Solene Patrat-Delon ◽  
Pierre-Louis Henaux ◽  
...  
Keyword(s):  
Renal Transplant ◽  
16S Rrna ◽  
Species Identification ◽  
Antibiotic Treatment ◽  
Renal Transplant Patient ◽  
Transplant Patient ◽  
Brain Biopsy ◽  
Content Type ◽  
Disseminated Infection ◽  
First Case

Here we report in a human, a renal transplant patient, the first disseminated infection withNocardia cerradoensis, isolated after a brain biopsy. Species identification was based on 16S rRNA,gyrB, andhsp65gene analyses. Antibiotic treatment was successful by combining carbapenems and aminoglycosides and then switching to oral trimethoprim-sulfamethoxazole.

scholarly journals Successful Treatment of Bloodstream Infection Due to Metallo-β-Lactamase-Producing Stenotrophomonas maltophilia in a Renal Transplant Patient

2016 ◽  
Vol 60 (9) ◽  
pp. 5130-5134 ◽  
Author(s):  
Maria F. Mojica ◽  
Christopher P. Ouellette ◽  
Amy Leber ◽  
M. Brian Becknell ◽  
Monica I. Ardura ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Stenotrophomonas Maltophilia ◽  
Conventional Treatment ◽  
Renal Transplant Patient ◽  
Transplant Patient ◽  
Opportunistic Pathogen ◽  
Multidrug Resistant ◽  
Content Type ◽  
Colistimethate Sodium ◽  
Novel Drug

ABSTRACTStenotrophomonas maltophiliais an emerging multidrug-resistant (MDR) opportunistic pathogen for which new antibiotic options are urgently needed. We report our clinical experience treating a 19-year-old renal transplant recipient who developed prolonged bacteremia due to metallo-β-lactamase-producingS. maltophiliarefractory to conventional treatment. The infection recurred despite a prolonged course of colistimethate sodium (colistin) but resolved with the use of a novel drug combination with clinical efficacy against the patient'sS. maltophiliaisolate.

scholarly journals Trichodysplasia spinulosa in a renal transplant patient: A case report of successful treatment

2020 ◽  
Vol 8 ◽  
pp. 2050313X2095303
Author(s):  
Camille Pennou ◽  
Eileen Javidi ◽  
Julie Lecours ◽  
Annie Bélisle ◽  
Sandra Davar
Keyword(s):  
Case Report ◽  
Renal Transplant ◽  
Transplant Recipient ◽  
Immunosuppressive Therapy ◽  
Kidney Transplant ◽  
Renal Transplant Patient ◽  
Transplant Patient ◽  
Kidney Transplant Recipient ◽  
Solid Organ ◽  
Immunocompromised Patients

Trichodysplasia spinulosa is a rare cutaneous disease caused by the trichodysplasia spinulosa–associated polyomavirus. It occurs more frequently in immunocompromised patients, particularly in solid organ transplants. A few successful treatments have been described in the literature. In our report, we present a biopsy-proven trichodysplasia spinulosa case in a kidney transplant recipient who rapidly responded to a reduction of his immunosuppressive therapy.

scholarly journals A Dutch Case Report of Successful Treatment of Chronic Relapsing Urinary Tract Infection with Bacteriophages in a Renal Transplant Patient

2019 ◽  
Vol 64 (1) ◽  
Author(s):  
Saskia Kuipers ◽  
Mike M. Ruth ◽  
Mike Mientjes ◽  
Ruud G. L. de Sévaux ◽  
Jakko van Ingen
Keyword(s):  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Renal Transplant ◽  
Tract Infection ◽  
Renal Transplant Patient ◽  
Transplant Patient ◽  
Recurrent Urinary Tract Infection ◽  
Gram Negative ◽  
Content Type ◽  
Transplant Patients

ABSTRACT We report a case of a 58-year-old renal transplant patient who developed a recurrent urinary tract infection with an extended-spectrum β-lactamase (ESBL)-positive Klebsiella pneumoniae strain in the first month posttransplant. Even though it tested susceptible to carbapenems and despite repeated meropenem treatment, his infection recurred. The infection eventually evolved into epididymitis that was successfully treated with meropenem and bacteriophages. This case demonstrates the difficulty of treating relapsing ESBL-positive Gram-negative infections in renal transplant patients.

scholarly journals Francisella philomiragia Bacteremia in a Patient with Acute Respiratory Insufficiency and Acute-on-Chronic Kidney Disease

2015 ◽  
Vol 53 (12) ◽  
pp. 3947-3950 ◽  
Author(s):  
Ryan F. Relich ◽  
Romney M. Humphries ◽  
H. Reid Mattison ◽  
Jessica E. Miles ◽  
Edward R. Simpson ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Renal Transplant ◽  
Kidney Disease ◽  
Chronic Granulomatous Disease ◽  
Renal Transplant Patient ◽  
Transplant Patient ◽  
Granulomatous Disease ◽  
Content Type ◽  
Near Drowning ◽  
Acute Respiratory Insufficiency

Francisella philomiragiais a very uncommon pathogen of humans. Diseases caused by it are protean and have been reported largely in near-drowning victims and those with chronic granulomatous disease. We present a case ofF. philomiragiapneumonia with peripheral edema and bacteremia in a renal transplant patient and review the diverse reports ofF. philomiragiainfections.

scholarly journals Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine Exposure

2016 ◽  
Vol 54 (12) ◽  
pp. 3028-3033 ◽  
Author(s):  
A. Jayakumar ◽  
R. M. Savic ◽  
C. K. Everett ◽  
D. Benator ◽  
D. Alland ◽  
...  
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Drug Exposure ◽  
Standard Dose ◽  
Rate Of Change ◽  
Time Curve ◽  
Content Type ◽  
Nonlinear Mixed Effects Model ◽  
Tb Treatment ◽  
Concentration Time ◽  
The Relationship

The Xpert MTB/RIF assay is both sensitive and specific as a diagnostic test. Xpert also reports quantitative output in cycle threshold ( C T ) values, which may provide a dynamic measure of sputum bacillary burden when used longitudinally. We evaluated the relationship between Xpert C T trajectory and drug exposure during tuberculosis (TB) treatment to assess the potential utility of Xpert C T for treatment monitoring. We obtained serial sputum samples from patients with smear-positive pulmonary TB who were consecutively enrolled at 10 international clinical trial sites participating in study 29X, a CDC-sponsored Tuberculosis Trials Consortium study evaluating the tolerability, safety, and antimicrobial activity of rifapentine at daily doses of up to 20 mg/kg of body weight. Xpert was performed at weeks 0, 2, 4, 6, 8, and 12. Longitudinal C T data were modeled using a nonlinear mixed effects model in relation to rifapentine exposure (area under the concentration-time curve [AUC]). The rate of change of C T was higher in subjects receiving rifapentine than in subjects receiving standard-dose rifampin. Moreover, rifapentine exposure, but not assigned dose, was significantly associated with rate of change in C T ( P = 0.02). The estimated increase in C T slope for every additional 100 μg · h/ml of rifapentine drug exposure (as measured by AUC) was 0.11 C T /week (95% confidence interval [CI], 0.05 to 0.17). Increasing rifapentine exposure is associated with a higher rate of change of Xpert C T , indicating faster clearance of Mycobacterium tuberculosis DNA. These data suggest that the quantitative outputs of the Xpert MTB/RIF assay may be useful as a dynamic measure of TB treatment response.

Sign in / Sign up

Export Citation Format

Share Document